Black cohosh associated mania in a patient with unipolar depression
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE
Authors: Yalcin, Murat; Oguz, Aysenur; Bestepe, Engin Emrem; Saglam, Nazife Gamze Usta; Ergelen, Mine
Abstract
Black cohosh (actaea racemosa, cimicifuga racemosa) a popular complementary medicine, is commonly prescribed as an alternative drug to hormone replacement therapy for the treatment of menopause symptoms and menstrual pain. Studies on the black cohosh's psychological effects are generally focused on the perimenopausal depression and anxiety; and, its effects have been considered to be affiliated with its serotonergic and dopaminergic activities. We report a patient presenting with acute onset mania associated with black cohosh use, probably due to its psychopharmacological activities on serotonergic and dopaminergic receptors. We suggest that black cohosh must be used cautiously in the patients with history of unipolar depression or bipolar disorder.
Towards precision medicine in generalized anxiety disorder: Review of genetics and pharmaco(epi)genetics
JOURNAL OF PSYCHIATRIC RESEARCH
Authors: Tomasi, Julia; Lisoway, Amanda J.; Zai, Clement C.; Harripaul, Ricardo; Muller, Daniel J.; Zai, Gwyneth C. M.; McCabe, Randi E.; Richter, Margaret A.; Kennedy, James L.; Tiwari, Arun K.
Abstract
Generalized anxiety disorder (GAD) is a prevalent and chronic mental disorder that elicits widespread functional impairment. Given the high degree of non-response/partial response among patients with GAD to available pharmacological treatments, there is a strong need for novel approaches that can optimize outcomes, and lead to medications that are safer and more effective. Although investigations have identified interesting targets predicting treatment response through pharmacogenetics (PGx), pharmaco-epigenetics, and neuroimaging methods, these studies are often solitary, not replicated, and carry several limitations. This review provides an overview of the current status of GAD genetics and PGx and presents potential strategies to improve treatment response by combining better phenotyping with PGx and improved analytical methods. These strategies carry the dual benefit of delivering data on biomarkers of treatment response as well as pointing to disease mechanisms through the biology of the markers associated with response. Overall, these efforts can serve to identify clinical, genetic, and epigenetic factors that can be incorporated into a pharmaco(epi)genetic test that may ultimately improve treatment response and reduce the socioeconomic burden of GAD.